Trade Vir Biotechnology VIR

Sell
 Buy

VirBiotechnology live chart

5m 15m 30m 1h 4h 1d 1w

Instrument Fundamentals

Weekly Search
Weekly
Daily
Date Close change Change (%) Open High Low

VirBiotechnology news

Latest news

Show more
Frances Wang 2025 Jun 12, 16:00

Stellar (XLM) Price Analysis: Where could XLM go in the upcoming days?

Stocks
Frances Wang 2025 Jun 12, 16:00

Crypto News Today: Bitcoin Price Down 1.85% as US PPI Rises

Cryptocurrencies
Ghko B 2025 Jun 12, 16:00

Dogecoin Price Prediction: Could Dogecoin Price Surge to $0.95?

Cryptocurrencies
Tommy Yap 2025 Jun 12, 16:00

Morning Note: Middle East Conflict Shakes Markets as Oil Soars, While AI Sector Eyes Growth

Morning Note Oil NVDA Tech
Ghko B 2025 Jun 11, 16:00

Crypto Market Sentiment: Crypto Fear and Greed Index Today

Cryptocurrencies
Tommy Yap 2025 Jun 11, 16:00

Morning Note: Adobe’s AI Momentum Leads Market Moves with Gold and Fed in Focus

Morning Note Gold Commodities Stocks
Ghko B 2025 Jun 10, 16:00

BTC USD Price Prediction: How much will Bitcoin be worth in 2030?

Cryptocurrencies
Ghko B 2025 Jun 10, 16:00

Wells Fargo Stock Slides 1.32%: Is Wells Fargo stock a good buy now?

Stocks

Info

Spread

0.05

Spread (%)

0.9653 %

Leverage

1:10

Overnight Interest Buy

-0.0597 %

Overnight Interest Sell

-0.0292 %

Currency

USD

Trading Hours

Markets closed

Friday

13:31 - 19:59

Monday

13:31-19:59

Tuesday

13:31-19:59

Wednesday

13:31-19:59

Thursday

13:31-19:59

Analysis and statistics

Open

---

Previous Close

---

52 Week High/Low

--- – ---

Market cap

725749504

Shares Outstanding

138238000

Earnings Date (Next)

0000-00-00

instr__dividend_date

instr__ex_dividend_date

instr__forward_annual_dividend_rate

0

instr__forward_annual_dividend_yield

0

EPS

-4.09

Learn more about this instrument

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Related Instruments

Asset
Sell
Buy
Change (%)

Trade Now

Trade Now

Trade Now

Trade Now
View all instruments

Latest Education Articles

Show more
Trustpilot